TY - JOUR
T1 - Randomized, placebo-controlled trial of sertraline and contingency management for the treatment of methamphetamine dependence
AU - Shoptaw, Steven
AU - Huber, Alice
AU - Peck, James
AU - Yang, Xiaowei
AU - Liu, Juanmei
AU - Jeff Dang, Dang
AU - Roll, John
AU - Shapiro, Benjamin
AU - Rotheram-Fuller, Erin
AU - Ling, Walter
N1 - Funding Information:
The authors gratefully acknowledge support from the National Institute on Drug Abuse for the conduct of this study and the analysis of these data from grants 1 R01 DA 010923 and 1 P50 DA 018185. Medication and placebo were provided by Pfizer Inc.
PY - 2006/10/15
Y1 - 2006/10/15
N2 - Background: Methamphetamine dependence and associated medical and psychiatric concerns are significant public health issues. This project evaluated the efficacy of sertraline (50 mg bid) and contingency management (CM) for the treatment of methamphetamine dependence. Method: In this randomized, placebo-controlled, double-blind trial, participants completed a 2-week non-medication baseline and were randomized to one of four conditions for 12 weeks: sertraline plus CM (n = 61), sertraline-only (n = 59), matching placebo plus CM (n = 54), or matching placebo-only (n = 55). All participants attended clinic thrice-weekly for data collection, medication dispensing, and relapse prevention groups. Outcomes included methamphetamine use (urine drug screening and self-reported days of use), retention (length of stay), drug craving (visual analogue scale), and mood symptoms (Beck Depression Inventory). Results: No statistically significant main or interaction effects for sertraline or CM in reducing methamphetamine use were observed using a generalized estimating equation (GEE), although post hoc analyses showed the sertraline-only condition had significantly poorer retention than other conditions (χ2 (3) = 8.40, p < 0.05). Sertraline conditions produced significantly more adverse events than placebo conditions. A significantly higher proportion of participants in CM conditions achieved three consecutive weeks of methamphetamine abstinence than those in non-CM conditions. Conclusions: These data do not demonstrate improved outcomes for sertraline versus placebo for treatment of methamphetamine dependence; indeed, they suggest sertraline is contraindicated for methamphetamine dependence. Findings provide support for the use of contingency management for treatment of methamphetamine dependence.
AB - Background: Methamphetamine dependence and associated medical and psychiatric concerns are significant public health issues. This project evaluated the efficacy of sertraline (50 mg bid) and contingency management (CM) for the treatment of methamphetamine dependence. Method: In this randomized, placebo-controlled, double-blind trial, participants completed a 2-week non-medication baseline and were randomized to one of four conditions for 12 weeks: sertraline plus CM (n = 61), sertraline-only (n = 59), matching placebo plus CM (n = 54), or matching placebo-only (n = 55). All participants attended clinic thrice-weekly for data collection, medication dispensing, and relapse prevention groups. Outcomes included methamphetamine use (urine drug screening and self-reported days of use), retention (length of stay), drug craving (visual analogue scale), and mood symptoms (Beck Depression Inventory). Results: No statistically significant main or interaction effects for sertraline or CM in reducing methamphetamine use were observed using a generalized estimating equation (GEE), although post hoc analyses showed the sertraline-only condition had significantly poorer retention than other conditions (χ2 (3) = 8.40, p < 0.05). Sertraline conditions produced significantly more adverse events than placebo conditions. A significantly higher proportion of participants in CM conditions achieved three consecutive weeks of methamphetamine abstinence than those in non-CM conditions. Conclusions: These data do not demonstrate improved outcomes for sertraline versus placebo for treatment of methamphetamine dependence; indeed, they suggest sertraline is contraindicated for methamphetamine dependence. Findings provide support for the use of contingency management for treatment of methamphetamine dependence.
KW - Contingency management
KW - Drug abuse
KW - Medications
KW - Methamphetamine
KW - Sertraline
UR - http://www.scopus.com/inward/record.url?scp=33748320854&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33748320854&partnerID=8YFLogxK
U2 - 10.1016/j.drugalcdep.2006.03.005
DO - 10.1016/j.drugalcdep.2006.03.005
M3 - Article
C2 - 16621339
AN - SCOPUS:33748320854
SN - 0376-8716
VL - 85
SP - 12
EP - 18
JO - Drug and alcohol dependence
JF - Drug and alcohol dependence
IS - 1
ER -